What happened
Par Health USA announced a nationwide, hospital/user-level recall of 22 lots of Argatroban Injection 250 mg/2.5 mL (100 mg/mL) after particulate matter was detected in certain lots. Identified materials included cellulose, polystyrene, polyethylene terephthalate, stopper material, and possibly stainless steel. The affected lots were distributed to wholesalers and hospitals between December 30, 2024, and May 5, 2026. Par Health stated that administration of affected product could cause life-threatening vascular and inflammatory consequences. No related adverse events had been reported. Wholesalers and hospital pharmacies were instructed to discontinue use and distribution immediately and return existing inventory.
Why it matters
From a pharmaceutical manufacturing perspective, the presence of multiple particulate materials in an injectable product may be relevant to contamination control, component and material oversight, and packaging system controls. The recall also highlights the importance of identifying affected lots, stopping distribution and use, notifying downstream accounts, and arranging inventory returns. The source does not identify the particulate sources or describe a manufacturing investigation.
Key topics: Argatroban Injection particulate matter recall, Cellulose, polymer, stopper, and possible stainless-steel particles, Nationwide hospital and wholesaler inventory return